Welab Barcelona, Parc Científic Barcelona, C/Baldiri Reixac 4-8,08028 Barcelona, Spain.
J Med Chem. 2023 Sep 14;66(17):12499-12519. doi: 10.1021/acs.jmedchem.3c01060. Epub 2023 Aug 22.
The synthesis and pharmacological activity of a new series of isoxazolylpyrimidines as sigma-2 receptor (σR) ligands are reported. Modification of a new hit retrieved in an HTS campaign allowed the identification of the compound WLB-89462 () with good σR affinity ( = 13 nM) and high selectivity vs both the σR ( = 1777 nM) and a general panel of 180 targets. It represents one of the first σR ligands with drug-like properties, linked to a good physicochemical and ADMET profile (good solubility, no CYP inhibition, good metabolic stability, high permeability, brain penetration, and high oral exposure in rodents). Compound shows neuroprotective activity in vitro and improves short-term memory impairment induced by hippocampal injection of amyloid β peptide in rats. Together with the promising effects in the chronic models where is currently being evaluated, these results pave the way toward its clinical development as a neuroprotective agent.
报告了一系列新型异噁唑嘧啶作为 sigma-2 受体(σR)配体的合成和药理学活性。对在高通量筛选(HTS)中发现的一个新的命中化合物进行修饰,鉴定出化合物 WLB-89462(),具有良好的 σR 亲和力(= 13 nM)和高选择性,与 σR(= 1777 nM)和 180 个靶标的一般靶标相比。它是具有类药性的首批 σR 配体之一,与良好的理化和 ADMET 特性相关(良好的溶解度、无 CYP 抑制、良好的代谢稳定性、高通透性、脑穿透性和在啮齿动物中的高口服暴露量)。化合物在体外具有神经保护活性,并改善了大鼠海马注射淀粉样β肽引起的短期记忆障碍。与正在评估中的慢性模型中的有希望的效果一起,这些结果为其作为神经保护剂的临床开发铺平了道路。